Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Interest Expenses (2022 - 2026)

Centessa Pharmaceuticals has reported Interest Expenses over the past 4 years, most recently at $2.8 million for Q4 2025.

  • Quarterly Interest Expenses rose 13.27% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, up 13.57% year-over-year, with the annual reading at $11.5 million for FY2025, 13.57% up from the prior year.
  • Interest Expenses was $2.8 million for Q4 2025 at Centessa Pharmaceuticals, down from $2.9 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $2.9 million in Q3 2025 and troughed at $1.5 million in Q1 2022.
  • The 4-year median for Interest Expenses is $2.5 million (2024), against an average of $2.4 million.
  • Year-over-year, Interest Expenses surged 56.33% in 2023 and then decreased 3.54% in 2024.
  • A 4-year view of Interest Expenses shows it stood at $2.2 million in 2022, then rose by 16.66% to $2.6 million in 2023, then decreased by 3.54% to $2.5 million in 2024, then grew by 13.27% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Interest Expenses are $2.8 million (Q4 2025), $2.9 million (Q3 2025), and $2.9 million (Q2 2025).